Yi-Ching Wang


Department of Pharmacology and Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University


Chair Professor


1988~1993 PhD, Genetics, Michigan State University, USA


2004, 2010, 2014 Outstanding research award of National Science Council / Ministry of Science and Technology (MOST), Taiwan

2007 Distinguished alumnus of Chinese Culture University, Taiwan

2008 Outstanding research award, Pharmacology Society, Taiwan

2008~2020 Research award of Cheng-Shin Medical Foundation, Taiwan

2010 Outstanding research award, College of Medicine, National Cheng Kung University, Taiwan

2013 Dr. Tung Ta-Cheng Memorial Award for Basic Cancer Research, Chinese Oncology Society, Taiwan

2017~2023 Merit MOST Research Fellow Award, Taiwan

2017 Dr. Wang Min-Ning Memory Foundation for Excellent Basic Medical Research award, Taiwan

2018 K. T. Li Honorary Scholar Award, Taiwan


Dr. Wang’s laboratory has a long-standing research interest on the molecular mechanisms involved in tumorigenesis. Dr. Wang investigates the etiological association of alterations in tumor suppressor genes and oncogenes in cancer signaling. Dr. Wang has continued to do research on cancer genomics and epigenomics for identification of new genes critical to lung tumorigenesis. Dr. Wang’s group identifies an oncogenic zinc finger transcription factor ZNF322A and investigates the underlying mechanisms of ZNF322A in cancer progression. More recently, Dr. Wang focuses on the role of Rab37 small GTPase in the regulation of exocytosis and malfunction of Rab37 in tumorigenesis and tumor microenvironment. Several potential anti-cancer drugs and immunomodulation antibodies are under development in her laboratory.


Selected publications (from a total of 115 peer-reviewed publications)

  1. Yang PS, Yu MH, Hou YC, Chang CP, Lin SC, Kuo IY, Su PC, Cheng HC, Su WC, Shan YS*, Wang YC*. 2022. Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy. Theranostics, 12(1):340-361 (cover article).

  2. Kuo IY, Yang YE, Yang PS, Tsai YJ, Tzeng HT, Cheng HC, Kuo WT, Su WC, Chang CP*, Wang YC*. 2021. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics 11(14):7029-7044 (cover article).

  3. Hsieh CH, Hsieh HC, Fu FH, Wang PW, Yang LX, Shieh DB*, Wang YC*. 2021. An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment. Theranostics, 11(14):7072-7091 (cover article).

  4. Jen J, Chen YT, Wu LT, Liu CY, Shieh YC, Lai WW, Wang YC*. 2019. Oncogenic zinc finger protein ZNF322A promotes stem cell-like properties in lung cancer through transcriptional suppression of c-Myc expression. Cell Death and Differentiation 26(7):1283-1298.

  5. Liao SY, Kuo IY, Chen YT, Liao PC, Liu YF, Wu HY, Lai WW, Wang YC*. 2019. AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression. Oncogene 38(41):6723-6736

  6. Tzeng HT, Su CC, Chang CP, Lai WW, Su WC, Wang YC*. 2018. Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype. Int. J. Cancer 143, 1753-1763 (cover article).

  7. Jen J, Tang YA, Lu YH, Lin CC, Lai WW, Wang YC*. 2017. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol Cancer 16(1):104 (highly cited article).

  8. Tzeng HT, Tsai CH, Yen YT, Cheng HC, Chen YC, Pu SW, Wang YS, Shan YS, Tseng YL, Su WC, Lai WW, Wu LW, Wang YC*. 2016. Dysregulation of Rab37-mediated cross-talk between cancer cells and endothelial cells via thrombospondin-1 promotes tumor neovasculature and metastasis. Clin. Cancer Res. 23(9):2335-2345 (highlighed article).

  9. Tang YA, Chen CH, Sun S, Cheng CP, Tseng VS, Hsu HS, Su WC, Lai WW, Wang YC*. 2015. Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer. Nucleic Acids Res. 43(3):1593-608.

  10. Tseng RC, Chang JM, Chen JH, Huang WR, Tang YA, Kuo IY, Yan JJ, Lai WW*, Wang YC*. 2015. Deregulation of SLIT2-mediated Cdc42 activity is associated with esophageal squamous carcinoma cancer metastasis and poor prognosis. J. Thorac. Oncol. 10(1):189-198.

  11. Tsai CH, Cheng HC, Wang YS, Lin P, Jen J, Kuo IY, Chang YH, Liao PC, Chen RH, Yuan WC, Hsu HS, Yang MH, Hsu MT, Wu CY, Wang YC*. 2014. Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumor metastasis. Nat Commun 5:4804 doi: 10.1038/ncomms5804.

12. Yang YC, Tang YA, Shieh JM, Lin RK, Hsu HS, Wang YC*. 2014. DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpression in lung cancer. J. Thorac. Oncol. 9(9):1305-15.

13. Tang YA, Lin RK, Tsai YT, Hsu HS, Yang YC, Chen CY, Wang YC*. 2012. MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer. Clin. Cancer Res. 18:4325-33.

14. Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY, Lu YY, Tang YA, Yang YC, Yang PC, Wang YC*. 2010. Dysregulation of p53/Sp1 control leads to DNA methyltransferase 1 overexpression in lung cancer. Cancer Res. 70:5807-5817 (highlighed article). 

15. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, Lee CF, Wang YC*. 2010. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J. Clin. Invest. 120:521–532 (cover article).